More than 10k cans of Coca-Cola voluntarily recalled over possible plastic contamination
More than 10,000 cans of Original Coca-Cola have been voluntarily recalled due to possible plastic contamination.
The recall was initiated by Coca-Cola manufacturer Reyes Coca-Cola Bottling on March 6 and was officially designated a Class II recall by the U.S. Food and Drug Administration on March 24, according to an FDA report.
According to the FDA, the Class II designation indicates that use of a recalled product could cause temporary or reversible health effects or that the probability of "serious adverse health consequences" is "remote."
In total, 864 12-count packs of Coco-Cola Original Taste cans are affected.
The recall only affects specific 12-ounce Coca-Cola Original cans produced by Reyes Coca-Cola Bottling, LLC in Milwaukee, Wisconsin. Only certain batches distributed in Illinois and Wisconsin are included.
Recall on Diet Coke, Fanta Orange and Sprite due to possible contamination
To check if your Coca-Cola is part of the recall, look for the following details on the can or packaging:
Can UPC: 0 49000-00634 6
Pack UPC: 0 49000-02890 4
Date code: Sept. 29, 2025 (SEP2925MDA)
Time stamp: 1100-1253
Labeling: "Canned Under Authority of the Coca-Cola Company, Atlanta, GA 30313."
Reached for comment Tuesday, Coca-Cola referred ABC News to Reyes Coca-Cola Bottling. In a statement, a spokesperson for the bottling company confirmed the voluntary recall.
"The cases are being withdrawn because they did not meet our high-quality standards," the spokesperson said. "We are taking this voluntary action because nothing is more important to us than providing high-quality products to the people who drink our beverages."
More than 10k cans of Coca-Cola voluntarily recalled over possible plastic contamination originally appeared on goodmorningamerica.com
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Insider
an hour ago
- Business Insider
Argenx presents new Efgartigimod data at EULAR 2025
argenx (ARGX) SE 'announced the presentation of positive results from Phase 2 studies evaluating VYVGART in Sjogren's disease and idiopathic inflammatory myopathies at the European Congress of Rheumatology, EULAR 2025, from June 11 – 14 in Barcelona, Spain. argenx also announced that the FDA has granted efgartigimod Fast Track designation for the treatment of primary Sjogren's disease.' Confident Investing Starts Here: Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Yahoo
an hour ago
- Yahoo
ClearPoint Neuro, Inc. (CLPT): A Bull Case Theory
We came across a bullish thesis on ClearPoint Neuro, Inc. (CLPT) on M.V. Cunha's Substack. In this article, we will summarize the bulls' thesis on CLPT. ClearPoint Neuro, Inc. (CLPT)'s share was trading at $13.93 as of 6th June. A medical doctor surrounded by advanced technology in the operating room. ClearPoint Neuro is transforming from a surgical tools provider into a critical platform company enabling the next generation of neurological treatments. In the first quarter of 2025, revenue grew 31 percent year-over-year to 8.5 million dollars, led by the rapid adoption of its SmartFrame operating room system, which increased 70 percent and allows hospitals to use ClearPoint technology in standard surgical settings. This expansion seeds a larger installed base and drives high-margin recurring revenue from disposable instruments. The biologics and drug delivery segment generated 4.7 million dollars in revenue, growing 9 percent year-over-year, and is supported by more than 60 active partnerships with gene and cell therapy developers. As these therapies move toward commercial use, ClearPoint's role as the enabling delivery infrastructure could become its most profitable revenue stream, with each procedure generating over 20,000 dollars in high-margin recurring revenue. Meanwhile, the company is intentionally moving away from capital equipment sales, which declined 63 percent, in favor of a subscription-based model that provides predictable recurring revenue. Operating cash burn fell 35 percent in 2024, with expenses rising 29 percent in the latest quarter due to targeted investments in preclinical services, therapy support, and device innovation. ClearPoint closed the quarter with 12.4 million dollars in cash and access to up to 105 million dollars in financing, providing sufficient capital to reach financial breakeven without near-term equity dilution. While risks around execution, partner dependency, and regulatory pacing remain, ClearPoint's embedded position across neurological therapy development offers investors a unique opportunity to benefit from a long-term transformation into the backbone of next-generation brain treatments. Previously, we highlighted a on ClearPoint Neuro from northeasternsvf in January 2025, which emphasized its unique position as the only FDA-cleared, MRI-guided neurosurgical platform enabling precise delivery of CNS gene and cell therapies. That thesis focused on the company's expanding biopharma partnerships, operating room penetration through SmartFrame OR, and its path to profitability via high-margin disposables. ClearPoint Neuro, Inc. (CLPT) is not on our list of the 30 Most Popular Stocks Among Hedge Funds. As per our database, 21 hedge fund portfolios held CLPT at the end of the first quarter which was 13 in the previous quarter. While we acknowledge the risk and potential of CLPT as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns, and doing so within a shorter timeframe. If you are looking for an AI stock that is more promising than CLPT but that trades at less than 5 times its earnings, check out our report about the cheapest AI stock. READ NEXT: 8 Best Wide Moat Stocks to Buy Now and 30 Most Important AI Stocks According to BlackRock. Disclosure: None. This article was originally published at Insider Monkey.
Yahoo
3 hours ago
- Yahoo
The Smartest Growth Stock to Buy With $1,000 Right Now
Consumer staples makers have long been able to grow their businesses through good and bad economic times. Some of the best consumer staples stocks are Dividend Kings. One consumer staple Dividend King has a good yield and attractive valuation. 10 stocks we like better than Coca-Cola › Quick, think about soda companies. What brand comes to mind? Probably Coca-Cola (NYSE: KO). That makes sense, given that Coca-Cola is one of the largest and best-known consumer staples brands in the world. But is it the smartest growth stock to buy if you have $1,000 to invest right now? Don't hit the buy button until you read about this high-yield alternative. From a big-picture perspective, Coca-Cola makes food, even though its products get their own category with the consumer staples space. Beverages are still a life necessity, even if its eponymous product is more for pleasure than need. The company is an industry powerhouse. Not only is Coke one of the best known, and most beloved, beverage brands, but Coca-Cola happens to have a massive distribution network, impressive marketing skills, and powerful research and development chops. The company's scale, meanwhile, gives it the wherewithal to act as an industry consolidator, buying up smaller brands and beverage concepts to round out its product portfolio. That, in turn, helps to keep Coca-Cola's brands relevant with consumers. The company's business is so strong that it has been a longtime holding of Warren Buffett within Berkshire Hathaway's stock portfolio. If Buffett has put billions into Coca-Cola, why shouldn't you put in $1,000? There's one notable reason: Investors have fully priced Coca-Cola's shares. The stock's price-to-sales ratio and its price-to-earnings ratio are both above their five-year averages, and the dividend yield is near 10-year lows. The business is doing relatively well right now, but virtually everyone seems to know it. One of the other factors that sets Coca-Cola apart is its status as a Dividend King. But it isn't the only Dividend King beverage company. Direct competitor PepsiCo (NASDAQ: PEP) has increased its dividend annually for 53 years and counting. Meanwhile, PepsiCo's price-to-sales and price-to-earnings ratios are below their five-year averages, and its yield is toward the high end of its historical range. So, unlike Coca-Cola, PepsiCo looks cheap. PepsiCo stands out on the valuation front, but it also stands out on the diversification front. Like Coca-Cola, it has a globally diversified business. But PepsiCo operates in the salty snack and packaged foods spaces, too. That gives it more levers to pull to support long-term growth and more businesses to lean on when one of its divisions is facing difficulty. And make no mistake, every company, no matter how good, eventually faces hard times. The best companies, which include Dividend Kings, are the ones that successfully manage through the hard times. While Coca-Cola is performing quite well today, PepsiCo isn't. That's why its yield is a historically high 4.3% and its stock price has lost a third of its value since early 2023. But PepsiCo isn't giving up. In fact, it is leaning on its successful playbook and buying smaller brands (Siete and Poppi) that are more relevant with consumers right now. That should, in time, help PepsiCo to get back on the growth track. If you're looking at Coca-Cola today, you should probably give PepsiCo a closer look. But don't just think about how each business is performing this very second. Think about their valuations in relation to their performance and, just as important, what each company is doing to ensure they succeed. They both have solid businesses and are working on a bright future, but PepsiCo isn't getting any credit for it because it is facing some near-term headwinds. If you can think long term, putting $1,000 into PepsiCo today could end up being a huge win for your future wealth. Note that one of the keys to Buffett's investment approach is buying good companies when they look attractively priced. Between Coca-Cola and PepsiCo, it is PepsiCo that passes that simple screen. Before you buy stock in Coca-Cola, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the for investors to buy now… and Coca-Cola wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $660,341!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $874,192!* Now, it's worth noting Stock Advisor's total average return is 999% — a market-crushing outperformance compared to 173% for the S&P 500. Don't miss out on the latest top 10 list, available when you join . See the 10 stocks » *Stock Advisor returns as of June 9, 2025 Reuben Gregg Brewer has positions in PepsiCo. The Motley Fool has positions in and recommends Berkshire Hathaway. The Motley Fool has a disclosure policy. The Smartest Growth Stock to Buy With $1,000 Right Now was originally published by The Motley Fool
